Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.49 |
| ▸ | LOX | P28300 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875692 | 0.86 | ADORA3 (0.76) | ADORA3SLC6A3CYP3A4LOXL2LOX | |
| SCHEMBL1062382 | 0.86 | ADORA3 (0.75) | ADORA3SLC6A3HTR6LOXL2LOX | |
| SCHEMBL5875745 | 0.82 | ADORA3 (0.69) | ADORA3SLC6A3HTR6LMNALOXL2 | |
| SCHEMBL1062638 | 0.82 | ADORA3 (0.69) | ADORA3SLC6A3LMNAMEN1KMT2A | |
| SCHEMBL5875752 | 0.80 | ADORA3 (0.67) | ADORA3SLC6A3HTR6TSHRCYP2C9 | |
| SCHEMBL9048270 | 0.77 | ADORA3 (0.62) | ADORA3SLC6A3TSHRLOXL2LOX | |
| SCHEMBL5875599 | 0.75 | ADORA3 (0.58) | ADORA3SLC6A3LMNALOXL2KMT2A | |
| Dapsone SCHEMBL9690505 | 0.73 | HTR6 (0.94) | ADORA3SLC6A3HTR6TSHRCYP2C9 | |
| SCHEMBL9046843 | 0.73 | ADORA3 (0.57) | ADORA3SLC6A3LOXL2LOXALDH1A1 | |
| SCHEMBL9049940 | 0.73 | ADORA3 (0.56) | ADORA3SLC6A3LOXL2LOXKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1603 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| CN-110845436-A | Thiazolesulfone compound and preparation and application thereof | 合肥锦绣田园化工科技有限公司 | 2020-02-28 | — | — | CN | claimed |
| US-10449247-B2 | Compositions and methods for enhancing immune response | AVIVAGEN INC. (CA) | 2019-10-22 | — | — | US | claimed |
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| CN-105492005-A | Methods of treating microbial infections including mastitis | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | claimed |
| CN-105492004-A | Method of treating topical microbial infections | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | claimed |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Limited (IE) | 2016-01-07 | — | — | US | claimed |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Limited (IE) | 2015-12-24 | — | — | US | claimed |
| EP-2953623-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0642337-B1 | DAPSONE AND PROMIN FOR THE TREATMENT OF DEMENTIA | UNIV BRITISH COLUMBIA (CA) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| US-5532219-A | ALZEHEIMER'S DISORDER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-07-02 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0642337-A1 | DAPSONE AND PROMIN FOR THE TREATMENT OF DEMENTIA. | UNIV BRITISH COLUMBIA (CA) | 1995-03-15 | — | — | EP | claimed |
| WO-1993024118-A1 | DAPSONE AND PROMIN FOR THE TREATMENT OF DEMENTIA | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1993-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | TSLP, CCL11, IL17A | ADORA3 3645/4885SLC6A3 2980/4885HTR6 4659/4885 |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LCT, TSLP, MLEC | ADORA3 4676/4885SLC6A3 3039/4885HTR6 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.